Radiation Therapy and Androgen Suppression as Treatment for Clinically Localized Prostate Cancer

Publisher Website
Google Scholar
Abstract
One of every 6 men living in the United States will be diagnosed with prostate cancer at some point in his life.1 Although the likelihood of death from such a diagnosis is much less than 1 in 6, nearly 30 000 men will die from prostate cancer this year.1 Many men who die from this disease were originally diagnosed with clinically significant tumors, which were palpable, of an intermediate to high grade on review of the needle biopsy specimen, and/or associated with a serum prostate specific antigen (PSA) of more than 10 ng/mL.2,3 The 10-year disease-free survival following surgical or nonsurgical therapy for such men is frequently less than 50%.4